CN117770431A - Application of Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drug - Google Patents
Application of Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drug Download PDFInfo
- Publication number
- CN117770431A CN117770431A CN202311686718.6A CN202311686718A CN117770431A CN 117770431 A CN117770431 A CN 117770431A CN 202311686718 A CN202311686718 A CN 202311686718A CN 117770431 A CN117770431 A CN 117770431A
- Authority
- CN
- China
- Prior art keywords
- lyophyllum decastes
- fruiting body
- lyophyllum
- decastes
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000005856 Lyophyllum decastes Species 0.000 title claims abstract description 132
- 235000013194 Lyophyllum decastes Nutrition 0.000 title claims abstract description 132
- 150000001875 compounds Chemical class 0.000 title claims abstract description 57
- 235000013305 food Nutrition 0.000 title claims abstract description 54
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229920001197 polyacetylene Polymers 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003472 antidiabetic agent Substances 0.000 title abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000002137 ultrasound extraction Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000005498 polishing Methods 0.000 claims description 12
- 239000008223 sterile water Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000013355 food flavoring agent Nutrition 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 79
- 210000004369 blood Anatomy 0.000 description 78
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 73
- 239000008103 glucose Substances 0.000 description 73
- 241000700159 Rattus Species 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- 206010022489 Insulin Resistance Diseases 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000017170 Lipid metabolism disease Diseases 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000018914 glucose metabolism disease Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000218554 Lyophyllum Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of a Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drugs, and belongs to the technical field of biological products. The invention takes the Lyophyllum decastes fruiting body as the only raw material, adopts the Lyophyllum decastes fruiting body superfine powder and the Lyophyllum decastes fruiting body polyacetylene compound to prepare the Lyophyllum decastes food, has the characteristics of unique ingredients, obvious efficacy, safety and stability and sufficient raw materials, and does not add any ingredients such as medicines, pigments, solid agents, flavoring agents, preservatives and the like into the product, thereby having excellent hypoglycemic effect.
Description
Technical Field
The invention relates to the technical field of biological products, in particular to an application of a Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drugs.
Background
Currently, the number of diabetics is increased, the prevalence rate reaches 11.6%, and the situation of increasing year by year is formed; diabetes has become the third most serious chronic disease threatening human health following tumor and cardiovascular disease; there is no cure recipe at present, once the patient suffers from the disease, the medicine is taken for life; furthermore, hyperglycemia has become an "intuitive complication" of cardiovascular disease in diabetics, as well as in high risk populations for developing cardiovascular disease, with 52.92% of coronary heart disease patients having diabetes.
The Lyophyllum decastes fruiting body contains 4 polyacetyl compounds: 3, 4-dihydroxy-2-hex-2, 4-diimine-2-tetrahydrofuran (1), (E) -2-dec-4, 6, 8-trien-1-ol (2), dehydromatrimony-ethyl ester (3), (E) -2-dec-4, 6, 8-trienoic acid (4), respectively.
The polyacetylene compound is a large chain conjugated system consisting of a plurality of alkenyl groups and alkynyl groups, has high unsaturation and chemical activity, is a special natural compound, and is a lotus leaf Lyophyllum extract rich in the polyacetylene compound, and the lotus leaf Lyophyllum extract has a promoting effect on glucose uptake; has effect in improving insulin resistance of adipocyte; can sensitize insulin, increase glucose uptake, improve insulin resistance state of adipocytes, and increase glucose uptake and utilization capacity of adipocytes. However, since the content of the polyacetylene compound in the fruit body of the Lyophyllum decastes is low, the dietetic effect of the Lyophyllum decastes is difficult to achieve after a long-term eating without a large amount of polyacetylene compound.
Disclosure of Invention
The invention aims to provide an application of a polyacetylene compound in Lyophyllum decastes fruiting bodies in preparation of Lyophyllum decastes food or hypoglycemic drugs, and can realize the application of the polyacetylene compound in Lyophyllum decastes fruiting bodies in food.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides an application of a Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food, and the preparation method of the Lyophyllum decastes food comprises the following steps:
mixing the superfine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and sterile water, granulating, polishing and drying sequentially to obtain the Lyophyllum decastes food.
Preferably, the preparation method of the Lyophyllum decastes fruiting body superfine powder comprises the following steps: sequentially drying and superfine pulverizing Lyophyllum decastes fruiting body to obtain Lyophyllum decastes fruiting body superfine powder; the diameter of the Lyophyllum decastes fruiting body superfine powder is less than or equal to 0.5 mu m.
Preferably, the temperature of the drying is 50-55 ℃, and the drying is carried out until the water content of the fruiting body is 12-13 wt%.
Preferably, the mass concentration of the Lyophyllum decastes fruit body polyacetyl compound in the Lyophyllum decastes fruit body polyacetyl compound concentrated solution is 78-80%; the dosage ratio of the ultra-fine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and the sterile water is 500 g:240-250 mL:40-50 mL.
Preferably, the preparation method of the Lyophyllum decastes fruiting body polyacetylene compound concentrate comprises the following steps:
mixing Lyophyllum decastes fruiting body powder with absolute alcohol, performing ultrasonic extraction of polyacetylene compounds, and separating to obtain extractive solution;
concentrating the extracting solution under reduced pressure to obtain concentrated solution of the Lyophyllum decastes fruiting body polyacetyl compound.
Preferably, the temperature of ultrasonic extraction of the polyacetylene compound is 55-60 ℃, the stirring speed is 35-40 r/min, the ultrasonic frequency is 18-20 KHz, the extraction times are 2 times, and the time of each extraction is independently 2.5-3 h.
Preferably, the conditions of the reduced pressure concentration include: the water bath temperature is 55-60 ℃, the rotation speed of an evaporating bottle is 20r/min, the vacuum degree is 0.05-0.07 MPa, and the condensation circulation temperature is-10 to-20 ℃.
Preferably, the drying temperature is 45-50 ℃, and the drying is carried out until the water content of the material is 12-13 wt%.
The invention provides an application of a Lyophyllum decastes fruiting body polyacetylene compound in preparing lipid-lowering drugs, and the preparation method of the lipid-lowering drugs comprises the following steps:
mixing the superfine powder of Lyophyllum decastes fruiting body, the concentrated solution of Lyophyllum decastes fruiting body polyacetylene compound and sterile water, granulating, polishing and drying sequentially to obtain the lipid-lowering medicine.
The invention takes the Lyophyllum decastes fruiting body as the only raw material, adopts the Lyophyllum decastes fruiting body superfine powder and the Lyophyllum decastes fruiting body polyacetylene compound to prepare the Lyophyllum decastes food through granulating, polishing and drying, has the characteristics of unique ingredients, obvious efficacy, safety and stability and sufficient raw materials, and does not add any ingredients such as medicines, pigments, solid agents, flavoring agents, preservatives and the like into the product, thereby having excellent hypoglycemic effect.
Further, the invention adopts the technologies of superfine grinding, ultrasonic extraction, purification, decompression concentration, granulation, polishing and drying to prepare the Lyophyllum decastes food, wherein the superfine grinding technology, the ultrasonic extraction technology, the decompression evaporation concentration and the like are adopted to improve the content of the polyacetylene compound in the polyacetylene compound concentrated solution of the Lyophyllum decastes fruiting body, thereby effectively improving the content (25.3-26.7wt%) of the polyacetylene compound in the food or the lipid-lowering medicament, ensuring the quality of the product and being convenient to eat, store and carry.
Detailed Description
The invention provides an application of a Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food, and the preparation method of the Lyophyllum decastes food comprises the following steps:
mixing the superfine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and sterile water, granulating, polishing and drying sequentially to obtain the Lyophyllum decastes food.
In the invention, the preparation method of the Lyophyllum decastes fruiting body superfine powder preferably comprises the following steps: sequentially drying and superfine pulverizing Lyophyllum decastes fruiting body to obtain Lyophyllum decastes fruiting body superfine powder; the diameter of the Lyophyllum decastes fruiting body superfine powder is preferably less than or equal to 0.5 mu m.
The invention preferably adopts the Lyophyllum decastes fruiting body which is mature in seventy-eight minutes, free of disease spots, free of insect food and free of impurities to prepare the superfine powder.
In the present invention, the drying temperature is preferably 50 to 55 ℃, more preferably 52 to 53 ℃, and the drying is performed until the water content of the fruiting body is preferably 12 to 13wt%; the drying is preferably carried out in an electrothermal blowing drying oven; the drying time is preferably 72 hours.
In the present invention, the ultrafine grinding is preferably performed by an ultrafine grinder.
In the invention, the mass concentration of the Lyophyllum decastes fruit body polyacetyl compound in the Lyophyllum decastes fruit body polyacetyl compound concentrated solution is preferably 78-80%, more preferably 79-80%; the dosage ratio of the superfine Lyophyllum decastes fruiting body powder, the Lyophyllum decastes fruiting body polyacetylene compound concentrated solution and sterile water is preferably 500 g:240-250 mL:40-50 mL, more preferably 500g:250mL:50mL.
In the invention, the preparation method of the Lyophyllum decastes fruiting body polyacetylene compound concentrate preferably comprises the following steps:
mixing Lyophyllum decastes fruiting body powder with absolute alcohol, performing ultrasonic extraction of polyacetylene compounds, and separating to obtain extractive solution;
concentrating the extracting solution under reduced pressure to obtain concentrated solution of the Lyophyllum decastes fruiting body polyacetyl compound.
The invention preferably adopts a traditional Chinese medicine slicing pulverizer to pulverize the fruiting body dried until the water content of the fruiting body is 12-13 wt% into pulverized powder with the particle size of 0.5-1 cm, thus obtaining the Lyophyllum decastes fruiting body powder.
In the present invention, the mass ratio of the Lyophyllum decastes fruiting body powder to absolute alcohol is preferably 1:10.
In the invention, the temperature of ultrasonic extraction of the polyacetylene compound is preferably 55-60 ℃, the stirring speed is preferably 35-40 r/min, the ultrasonic frequency is preferably 18-20 KHz, the extraction times are preferably 2 times, the time of each extraction is independently preferably 2.5-3 h, and more preferably 2.6-2.8 h; the ultrasonic extraction and separation process of the polyacetylene compound is preferably as follows: putting the Lyophyllum decastes fruiting body powder into an ultrasonic extraction tank, soaking for 10-12 h, controlling the solvent temperature to 55-60 ℃ and the stirring speed to 35-40 r/min, continuously extracting for 2.5-3 h by ultrasonic waves at 18-20 KHz, and then filtering by a filter screen with 150-200 meshes to separate solid from liquid to obtain filtrate, thus completing the first extraction; adding absolute alcohol into an ultrasonic extraction tank, extracting for the second time under the same extraction conditions, and filtering to obtain filtrate; combining the two extracting solutions to obtain an extracting solution.
In the present invention, the conditions for the reduced pressure concentration preferably include: the extract was concentrated under reduced pressure using a rotary evaporator. Setting and controlling the water bath temperature to 55-60 ℃, the rotation speed of an evaporation bottle to 20r/min, the vacuum degree of decompression to 0.05-0.07 mpa and the condensation circulation temperature to-10 to-20 ℃ until alcohol is completely evaporated, and obtaining a concentrated solution of the polyacetylene compound; the water bath temperature is more preferably 56-58 ℃, the decompression vacuum degree is more preferably 0.06MPa, and the condensation circulation temperature is more preferably-15-18 ℃.
In the invention, the ultra-fine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and sterile water are mixed, then a food stirrer is added, the stirrer is started, the stirring is carried out at a low speed (25-30 r/min) for 4-5 min, at a medium speed (35-40 r/min) for 2-3 min and at a high speed (55-60 r/min) for 4-5 min until the materials are uniformly mixed; then granulating by a traditional Chinese medicine granulator, polishing the prepared pellets by a traditional Chinese medicine polishing machine for 8-10 min, placing the polished pellets in a dry hot blast drying box, and drying until the water content is 12-13 wt% to obtain Lyophyllum decastes food; the drying temperature is preferably 45-50 ℃, the time is preferably 68-72 h, and the drying is carried out until the water content of the material is preferably 12-13 wt%.
The invention provides an application of a Lyophyllum decastes fruiting body polyacetylene compound in preparing lipid-lowering drugs, and the preparation method of the lipid-lowering drugs comprises the following steps:
mixing the superfine powder of Lyophyllum decastes fruiting body, the concentrated solution of Lyophyllum decastes fruiting body polyacetylene compound and sterile water, granulating, polishing and drying sequentially to obtain the lipid-lowering medicine.
The process of mixing the superfine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and sterile water and granulating, polishing and drying sequentially is preferably the same as that described above, and is not repeated here.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Harvesting fresh, mature, disease-spot-free, insect-free and impurity-free Lyophyllum decastes fruiting body, placing in a 55 ℃ dry hot blast drying oven, maintaining for 72h, and drying to make the fruiting body water content 12% to obtain dried Lyophyllum decastes fruiting body;
crushing dried Lyophyllum decastes fruiting body into powder with size of 0.5cm by using a traditional Chinese medicine slicing crusher, weighing 1.5kg, adding 15kg of food-grade absolute alcohol according to a mass ratio of 1:10 into an ultrasonic extraction tank, soaking for 12h, setting and controlling the solvent temperature to 60 ℃, stirring speed to 40r/min, ultrasonic wave to 20KHz, continuously extracting for 3h, and filtering with a 200-mesh filter screen to obtain filtrate, thereby completing the first extraction; adding 12kg of absolute alcohol into an ultrasonic extraction tank, performing secondary extraction under the same extraction conditions, and filtering to obtain filtrate and filter residue; mixing the two extractive solutions to obtain extractive solution;
concentrating the extract under reduced pressure by a rotary evaporator, setting and controlling the water bath temperature to 90 ℃, the rotation speed of an evaporation bottle to 20r/min, the vacuum degree of reduced pressure to 0.07MPa, and the condensation circulation temperature to-20 ℃ until the water content of polysaccharide reaches 32%, so as to obtain a concentrated solution of the Lyophyllum decastes polyacetyl compound, wherein the mass concentration of the Lyophyllum decastes fruiting body polyacetyl compound in the concentrated solution is 80%;
pulverizing dried Lyophyllum decastes fruiting body into fine powder with particle diameter less than or equal to 0.5 μm by an ultrafine pulverizer to obtain Lyophyllum decastes fruiting body ultrafine powder, weighing 500g of the prepared Lyophyllum decastes fruiting body ultrafine powder, 240mL of Lyophyllum decastes polyacetyl compound concentrate (1500 g fruiting body extraction amount), weighing 50mL of sterile water, sequentially adding into a food stirrer, starting the stirrer, stirring at low speed (30 r/min) for 5min, stirring at medium speed (40 r/min) for 3min, stirring at high speed (60 r/min) for 5min until uniform mixing, granulating by a traditional Chinese medicine granulator, polishing the obtained pill with a traditional Chinese medicine polisher for 10min, placing the polished pill in a dry-hot blast drying box at 50deg.C for 72h, drying until the water content is 12%, and the particle weight is 0.085g to obtain Lyophyllum decastes food or lipid-lowering drug, and the Lyophyllum decastes polyacetyl compound content is 26.7wt%.
Test case
1. Experimental animal
SD rats, SPF grade, body weight 150-170g, male, 72; purchased from si Bei Fu (beijing) biotechnology limited, license number: SCXK (Beijing) 2019-0010. Raising in SPF-class animal house at room temperature of 24+ -2deg.C and relative humidity of 40-70%.
2. Materials and reagents
Tetraoxypyrimidine, 5 g/bottle, beijing Soy Bao technology Co., ltd; glucose, 500 g/bottle, shanghai Yuan Ye Biotechnology Co., ltd; GA-3 type blood sugar test paper, sanuo biosensing Co., ltd; insulin ELISA kit, nanjing builds biological engineering research all company limits; triglyceride assay kit, north-control biotechnology, inc; total cholesterol assay kit, north-control biotechnology, inc.
3. High heat energy feed
High heat energy feed components: 10% of lard, 15% of sucrose, 15% of egg yolk powder, 5% of casein, 1.2% of cholesterol, 0.2% of sodium cholate, 0.6% of calcium bicarbonate, 0.4% of stone powder and 52.6% of mouse maintenance feed;
the high heat energy feed is produced by Beijing Wanhukang biotechnology Co., ltd., license number: SCXK (jing) 2019-0008;
the murine maintenance feed was derived from the Beijing Warcang Biotechnology Co., ltd.
4. Instrument for measuring and controlling the intensity of light
GA-3 type blood glucose meter, sanuo biosensing Co., ltd; MP3KC electronic balance, shanghai, shunfu Hengping-Hengping electronic Co., ltd; MULTISKAN FC microplate reader, siemens instruments, inc.; GTR10-1 high-speed refrigerated centrifuge, beijing era North centrifuge Co., ltd; ME204/02 electronic analytical balance, mettler-Tolyduo instruments (Shanghai) Inc.; HITACHI 3100 full-automatic biochemical analyzer, japanese diagnostic products (Shanghai Co., ltd.).
4.1 dose grouping and time of administration of test samples
Sample to be tested: the Lyophyllum decastes food prepared in example 1 was dissolved in water to form aqueous solutions of different dosage concentrations, including Lyophyllum decastes food (1.0 g/kg) and Lyophyllum decastes food (1.5 g/kg);
test subjects 2 dose groups: lyophyllum decastes food (1.0 g/kg), lyophyllum decastes food (1.5 g/kg), blank control group and model control group. The test sample was administered for 30 days.
4.2 Experimental methods
4.2.1 blood glucose lowering experiments in Normal animals
Healthy adult animals were selected and grouped by blood glucose level for 4 hours of fasting, 1 control group and 1 dose group: lyophyllum decastes food (1.5 g/kg). The control group was given distilled water, the test substance was given to the test substance at a high dose concentration (1.5 g/kg) for 30 consecutive days, and the fasting blood glucose level (before the fasting and the experiment) was measured, and the blood glucose levels of the animals of the respective groups were compared.
4.2.2 principle of hypoglycemic experiment of hyperglycemia model
On the basis of high heat energy feed feeding, tetraoxypyrimidine (C 4 H 2 N 2 O 4 ·H 2 O, molecular weight 160.08), causes disorder of glucose/lipid metabolism, insulin resistance, and induces experimental diabetes.
4.3 method of Forming mold
Healthy male rats are purchased, the normal maintenance feed is adapted to feed for 3-5 days, fasting is carried out for 4 hours, tail blood is taken, the blood glucose value before glucose administration (namely 0 hour) is measured, and the blood glucose value after BW glucose of 2.5g/kg is given for 0.5 hour and 2 hours is taken as the basic value of animals in the batch. 6 groups, namely 1 blank control group, 1 model control group and 2 dose groups, each group of 12, were divided into 0, 0.5 hour blood glucose levels. The blank control group was not treated, and 2 dose groups were given different concentrations of test samples (1.0 g/kg and 1.5 g/kg) by gavage, and the model control group was given distilled water of the same volume as the dose group for 33 consecutive days.
After each group was fed with maintenance feed for 1 week, the model control group and 2 dose groups were changed for high-heat feed, and after 3 weeks of feeding, the model control group and 2 doses were fasted for 24 hours (without water inhibition), and a 105mg/kg BW intraperitoneal injection of tetraoxapyrimidine was given in an amount of 1mL/100g body weight. The high heat feed was fed for 5 days after injection. At the end of the test, animals of each group were fasted for 4 hours and tested for fasting blood glucose, glucose tolerance, serum insulin, cholesterol and triglyceride levels.
4.4 observations index
4.4.1 fasting blood glucose, glucose tolerance
Each group of animals fasted for 4 hours, blood sugar level before fasting blood sugar is measured, namely blood sugar level before glucose is given (0 hour), different concentrations of test samples are given to a dosage group, the same volume of solvent is given to a model control group, a blank control group is not treated, 2.5g/kg BW of glucose is given orally to each group after 20 minutes, blood sugar level of 0.5 hour and 2 hours after glucose is measured, if the blood sugar level of the model control group is more than or equal to 10mmol/L in 0.5 hour, or the blood sugar level of the model control group is increased at any time point of 0.5 hour and 2 hours or the area under a blood sugar curve is increased, compared with the blank control group, the difference is significant, and the establishment of model sugar metabolism disorder is judged, on the basis, the change of the areas under the blood sugar level curve of the model control group and the test sample groups after fasting blood sugar and glucose are given (0.5 hour and 2 hour) blood sugar level and 0.5 hour and 2 hour is observed.
Blood glucose decrease%o = (blood glucose before experiment-blood glucose after experiment)/(blood glucose before experiment × area under 100% blood glucose curve = (blood glucose at 0 hours+blood glucose at 0.5 hours) × 0.5 ++2 (blood glucose at 2 hours+blood glucose at 0.5 hours) × 1.5 ++2
4.4.2 cholesterol, triglycerides
Each group of animals is fasted for 4 hours, serum cholesterol and triglyceride are detected, if the serum cholesterol or triglyceride of the model control group is obviously increased, compared with the blank control group, the difference is obvious, and the establishment of the model lipid metabolism disorder is judged, and on the basis, the blood lipid change of the model control group and the blood lipid change of the tested sample group are observed.
4.4.3 insulin
Each group of animals is fasted for 4 hours, serum insulin is detected, the insulin resistance index is not obviously reduced compared with the model control group and the blank control group, and animal glucose/lipid metabolism disorder is established, so that the success of the insulin resistance glucose/lipid metabolism disorder model is judged. The insulin resistance of the model control group and the test sample group was observed.
Insulin resistance index = insulin/22.5 e-ln glycemia ≡glycemia x insulin/22.5.
4.5 data processing and result determination
Performing variance alignment detection by adopting variance analysis according to a variance analysis program, calculating an F value, wherein the F value is smaller than F0.05, and conclusion is that: the difference between the average numbers of the groups is not significant; f value is more than or equal to F0.05, P is less than or equal to 0.05, and statistics is carried out by a pairwise comparison method of average numbers between a plurality of experimental groups and a control group; proper variable conversion is carried out on the data with non-normal or variance, and statistics is carried out on the converted data after the normal or variance alignment requirement is met; if the normal or variance alignment purpose is not achieved after the variable conversion, the rank sum test is used for statistics.
4.6 index determination
4.6.1 test for reducing blood sugar in Normal animals
Blood glucose index: the dosage group of the sample for fasting blood glucose has no statistical significance compared with the control group, and the blood glucose of normal animals is judged to be not influenced.
4.6.2 hypoglycemic test of hyperglycemia model
Fasting blood glucose index: on the premise that the model is established, the dose group of the sample to be tested is compared with the model control group, the fasting blood glucose is reduced or the blood glucose reduction percentage is increased, which has statistical significance, and the fasting blood glucose index result of the sample to be tested is judged to be positive.
4.6.3 sugar tolerance index: on the premise that the model is established, comparing the tested sample dosage group with the model control group, and judging that the tested sample glucose tolerance index result is positive, wherein the blood glucose is reduced (or the blood glucose reduction percentage is increased) at any time point of 0.5 and 2 hours after glucose or medical starch is fed, or the area reduction under the blood glucose curve of 0, 0.5 and 2 hours is statistically significant.
4.6.4 blood lipid index: on the premise that the model is established, the dose group of the tested sample is compared with the model control group, and the reduction of serum cholesterol or triglyceride has statistical significance, so that the positive blood lipid reduction index of the tested sample can be judged.
5. Conclusion determination
One of the two indexes of fasting blood glucose and glucose tolerance is positive, blood fat (total cholesterol and triglyceride) is not obviously increased, and the test result of the tested sample which is helpful for maintaining blood glucose health level of animals can be judged to be positive without influencing the fasting blood glucose of normal animals.
6. Test results
6.1 Effect on body weight of normal rats
There was no significant change in body weight of Lyophyllum decastes food (1.5 g/kg) rats in the group compared to the placebo group.
TABLE 1 influence on body weight of normal ratsn＝12)
Note that: p <0.05, P <0.01 compared to the blank.
6.2 Effect on fasting blood glucose in Normal rats
After 30 days of continuous administration of the test sample, compared with the blank control group, the difference of fasting blood glucose of rats in the Lyophyllum decastes food (1.5 g/kg) group has no statistical significance and has no influence on blood glucose of normal rats.
TABLE 2 influence on fasting blood glucose in normal ratsn＝12)
Note that: p <0.05, P <0.01 compared to the blank.
6.3 Effect on body weight of hyperglycemic model rats
Compared with the blank control group, the body weight of the rats in the model control group has no obvious change; no significant change in weight was observed in rats in the Lyophyllum decastes food (1.0 g/kg) and Lyophyllum decastes food (1.5 g/kg) groups at the same time point as the model control group.
TABLE 3 influence on the body weight of hyperglycemic model ratsn＝12)
Note that: p <0.05, P <0.01 compared to the blank; compared to the model control group, #p <0.05, #p <0.01.
6.4 fasting blood glucose and glucose tolerance changes in hyperglycemia model rats
After the last administration, each group of animals is fasted for 4 hours, and the fasting blood sugar is respectively measured, namely, the blood sugar before glucose is given (0 hour), the blood sugar before glucose is given for 0.5 hour and the blood sugar before glucose is given for 2 hours; compared with the blank control group, the blood sugar of the rats in the model control group is extremely remarkably increased in 2h, the rats in the model control group are fasting (0 h) and 0.5h blood sugar, and the area under the blood sugar curve is not obviously increased. Compared with a model control group, the areas under the curves of the Lyophyllum decastes food (1.0 g/kg) and the Lyophyllum decastes food (1.5 g/kg) of rats with fasting blood glucose (0 h), blood glucose after glucose administration (0.5 and 2 h) and blood glucose after glucose administration (0.5 and 2 h) are obviously changed, and no statistical difference exists; lyophyllum decastes food (1.5 g/kg) group 0.5 hours showed significantly lower blood glucose than model control group rats. Judging that the index result of the Lyophyllum decastes food (1.5 g/kg) sample is positive.
TABLE 4 influence on fasting blood glucose and glucose tolerance in hyperglycemia model ratsn＝12)
Note that: p <0.05, P <0.01 compared to the blank; compared with the model control group, #P <0.05, #P <0.01
6.5 effects on serum cholesterol, triglycerides in hyperglycemic model rats
Compared with the blank control group, the serum cholesterol and triglyceride of the rats in the model control group are obviously increased (P <0.05 and P < 0.01), and the significant difference exists. Compared with the model control group, the TC and TG of the Lyophyllum decastes food (1.0 g/kg) group rats are not obviously reduced; both serum TC and TG of Lyophyllum decastes food (1.5 g/kg) group rats were significantly reduced (P <0.05, P < 0.01), with significant differences.
TABLE 5 influence on serum cholesterol and triglyceride in hyperglycemic model ratsn＝12)
Note that: p <0.05, P <0.01 compared to the blank; compared to the model control group, #p <0.05, #p <0.01.
6.5 insulin (insulin resistance index)
Animals were fasted for 4 hours, and the insulin resistance index was not significantly reduced in comparison with the model control group and the blank control group. Compared with the model control group, the serum insulin of rats in the Lyophyllum decastes food (1.0 g/kg) and Lyophyllum decastes food (1.5 g/kg) has no obvious change and no statistical difference.
TABLE 6 insulin resistance index variation of hyperglycemia model ratsn＝12)
Note that: p >0.05 compared to the model control group.
From the above examples and experiments, it can be seen that:
compared with a blank control group, the Lyophyllum decastes food (1.5 g/kg) provided by the invention has no statistical difference in fasting blood glucose and has no influence on normal rat blood glucose.
Compared with the blank control group, the fasting (0 h) and 0.5h blood sugar of the rats in the model control group are not obviously changed, the blood sugar of the rats in the model control group is obviously increased after 2h blood sugar of the rats in the model control group is obviously changed, and the metabolic disorder of the model sugar is established. Compared with a model control group, the areas under the curves of fasting blood glucose (0 h), blood glucose after glucose administration (0.5 and 2 h) and blood glucose after 0, 0.5 and 2h of Lyophyllum decastes food (1.0 g/kg) are obviously changed, and no statistical difference exists; lyophyllum decastes food (1.5 g/kg) group 0.5 hours showed significantly lower blood glucose than model control group rats. Judging that the index result of the Lyophyllum decastes food (1.5 g/kg) sample is positive.
Compared with the blank control group, the serum cholesterol and triglyceride of the rat in the model control group are obviously increased, the significant difference exists, and the model lipid metabolism disorder is established. Compared with the model control group, the Lyophyllum decastes food (1.0 g/kg) group of rats TC and TG have no statistical difference; the serum TC and TG of Lyophyllum decastes food (1.5 g/kg) are obviously reduced (P <0.05, P < 0.01) compared with the model control group, and the food has statistical significance.
The model control group and the blank control group have no obvious decrease in insulin resistance index, and animal glucose/lipid metabolism disorder is established, which indicates that the insulin resistance glucose/lipid metabolism disorder model is successful. Compared with the model control group, the serum insulin of rats in the Lyophyllum decastes food (1.0 g/kg) and Lyophyllum decastes food (1.5 g/kg) has no obvious change and no statistical difference.
The standard of decision for helping to maintain the blood sugar health level in the health food function test and evaluation method (2022 edition) issued by the national market supervision administration (solicited opinion manuscript) is known, and the sample is: lyophyllum decastes food (1.5 g/kg) helps to maintain blood glucose health level, and animal experiment result accords with positive result judgment. Namely, the Lyophyllum decastes food used in the invention has remarkable effect of reducing and maintaining the blood sugar of rats when being fed to rats at a feeding rate of 1.5g/kg per day, and is expected to become an ideal food for diabetics.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (9)
1. An application of a Lyophyllum decastes fruiting body polyacetylene compound in preparing Lyophyllum decastes food, wherein the preparation method of the Lyophyllum decastes food comprises the following steps:
mixing the superfine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and sterile water, granulating, polishing and drying sequentially to obtain the Lyophyllum decastes food.
2. The use according to claim 1, wherein the preparation method of the ultra-fine powder of Lyophyllum decastes fruiting body comprises: sequentially drying and superfine pulverizing Lyophyllum decastes fruiting body to obtain Lyophyllum decastes fruiting body superfine powder; the diameter of the Lyophyllum decastes fruiting body superfine powder is less than or equal to 0.5 mu m.
3. Use according to claim 2, wherein the drying is carried out at a temperature of 50-55 ℃ to a moisture content of the fruiting body of 12-13 wt%.
4. The use according to claim 1, wherein the mass concentration of the Lyophyllum decastes fruit body polyacetyl compound in the Lyophyllum decastes fruit body polyacetyl compound concentrate is 78-80%; the dosage ratio of the ultra-fine powder of the Lyophyllum decastes fruiting body, the concentrated solution of the Lyophyllum decastes fruiting body polyacetylene compound and the sterile water is 500 g:240-250 mL:40-50 mL.
5. The use according to claim 1 or 4, wherein the process for preparing a concentrated liquid of a polyethylenic compound of the fruit body of Lyophyllum decastes comprises the steps of:
mixing Lyophyllum decastes fruiting body powder with absolute alcohol, performing ultrasonic extraction of polyacetylene compounds, and separating to obtain extractive solution;
concentrating the extracting solution under reduced pressure to obtain concentrated solution of the Lyophyllum decastes fruiting body polyacetyl compound.
6. The use according to claim 5, wherein the temperature of ultrasonic extraction of the polyacetylene compound is 55-60 ℃, the stirring speed is 35-40 r/min, the ultrasonic frequency is 18-20 KHz, the extraction times are 2 times, and the time of each extraction is independently 2.5-3 h.
7. The use according to claim 5, wherein the conditions of reduced pressure concentration comprise: the water bath temperature is 55-60 ℃, the rotation speed of an evaporating bottle is 20r/min, the vacuum degree is 0.05-0.07 MPa, and the condensation circulation temperature is-10 to-20 ℃.
8. Use according to claim 1, characterized in that the drying is carried out at a temperature of 45-50 ℃ to a moisture content of 12-13 wt%.
9. The application of the Lyophyllum decastes fruiting body polyacetylene compound in preparing lipid-lowering drugs comprises the following steps:
mixing the superfine powder of Lyophyllum decastes fruiting body, the concentrated solution of Lyophyllum decastes fruiting body polyacetylene compound and sterile water, granulating, polishing and drying sequentially to obtain the lipid-lowering medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311686718.6A CN117770431A (en) | 2023-12-08 | 2023-12-08 | Application of Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311686718.6A CN117770431A (en) | 2023-12-08 | 2023-12-08 | Application of Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117770431A true CN117770431A (en) | 2024-03-29 |
Family
ID=90386005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311686718.6A Pending CN117770431A (en) | 2023-12-08 | 2023-12-08 | Application of Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117770431A (en) |
-
2023
- 2023-12-08 CN CN202311686718.6A patent/CN117770431A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113150867A (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| CN110448642B (en) | Rhizoma polygonati fermentation product, preparation method and application | |
| CN108186690A (en) | A kind of Chinese medicine processing method | |
| JP3069686B2 (en) | Flavanone-containing composition | |
| CN116036194A (en) | Traditional Chinese medicine composition, wine and preparation method and application thereof | |
| CN111528470A (en) | Preparation method of calcium roxburgh rose complex, product and application thereof | |
| CN106923337A (en) | A kind of preparation method and applications of spirulina full agonist | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| CN114832022B (en) | Preparation of Phellinus linteus fruiting body phenol active substances and application thereof in regulating intestinal flora and uric acid metabolism | |
| CN101007017A (en) | Extract of traditional Chinese medicine having alpha-glucosidase inhibitor activity and its application | |
| CN109985086B (en) | Cyclocarya paliurus leaf instant powder and preparation method thereof | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN1864530A (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN101744844B (en) | Fulvic acid or sodium fulvate substance with hypoglycemic function | |
| CN111248440B (en) | Functional jasmine flower oligosaccharide oral liquid and application thereof | |
| CN110448590B (en) | Oriental millettia root extract with sexual function enhancing effect, and preparation method and application thereof | |
| CN104673614A (en) | Pearl wine and preparation method thereof | |
| CN117770431A (en) | Application of Lyophyllum decastes fruiting body polyacetylene compound in preparation of Lyophyllum decastes food or hypoglycemic drug | |
| CN106668326B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN111700927B (en) | Medicinal and edible composition with blood sugar reducing effect and preparation method and application thereof | |
| CN100484539C (en) | Functional food with blood sugar reducing action and its preparing method | |
| CN108159146B (en) | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof | |
| CN114145374A (en) | Astragalus membranaceus and corn stigma composite tea and preparation method and application thereof | |
| CN114533817A (en) | Composition for improving blood sugar and/or blood fat and application thereof | |
| CN108969580B (en) | Preparation method and application of blue cloth total tannin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |